
Bristol-Myers Squibb Company
BMYNYSE
USReal-Time Price
$62.32USD
-0.59 (-0.94%)Today
$62.50+0.18 (+0.29%)After HoursLast quote · Nov 12, 2026, 4:43 PM ET
Investors Sentoments
Sign in to share your view.
BTI Score
BASIC required or higher
View pricingBTI Fair Market Cap
$132.22B
-3.65% vs fair
Healthcare & Pharma
Hold
Bristol-Myers Squibb Company (BMY) Stock Analysis
BTI's proprietary analysis of Bristol-Myers Squibb Company (BMY): overall score, long- and short-term outlook, risk rating and fair-value verdict based on fundamentals, valuation and momentum.
Major-Firm Consensus
Hold
Filtered to 34 major global investment banks
Buy
14
Hold
19
Sell
1
Price Target Consensus
High
$80.00
Consensus
$65.25
Low
$40.00
Current
$62.32
Upside: +4.7%
Target Trend
Last Month— (0)
Last Quarter— (0)
Last Year— (0)
Ratings History — Major Investment Banks
| Firm | Rating | Action | Previous | Price Target | Upside | Date |
|---|---|---|---|---|---|---|
| BMO Capital | Hold | Maintains | — | $60.00 | -3.7% | Nov 10, 2026 |
| RBC Capital | Hold | Maintains | — | $64.00 | +2.7% | Nov 5, 2026 |
| Bernstein | Hold | Maintains | — | $61.00 | -2.1% | Nov 3, 2026 |
| Wells Fargo | Hold | Maintains | — | — | — | Oct 30, 2026 |
| Morgan Stanley | Sell | Reiterates | — | — | — | Oct 30, 2026 |
| Scotiabank | Hold | Maintains | — | $60.00 | -3.7% | Oct 30, 2026 |
| Cantor Fitzgerald | Hold | Maintains | — | $53.00 | -15.0% | Oct 30, 2026 |
| Guggenheim | Buy | Reiterates | — | $75.00 | +20.3% | Oct 30, 2026 |
Annual Analyst Estimates
| Fiscal Year | Revenue Avg | Revenue Range | EPS Avg | EPS Range | Analysts |
|---|---|---|---|---|---|
| FY 2026 | $50.23B | — – — | $6.44 | — – — | — |
| FY 2027 | $48.80B | — – — | $6.70 | — – — | — |
Want deeper AI-powered analysis?
Get BTI AI's full investment thesis, valuation models, and risk assessment for BMY.


